Seven-year exclusivity and beyond for drugs of rare diseases in China

Yale Jiang; Huiyao Huang; Guo Zhao; Peiwen Ma; Liang Zhang; Shuhang Wang; Ning Li

doi:10.3389/fphar.2023.1223056

Seven-year exclusivity and beyond for drugs of rare diseases in China

Front Pharmacol. 2023 Oct 12:14:1223056. doi: 10.3389/fphar.2023.1223056. eCollection 2023.

Authors

Yale Jiang^#¹, Huiyao Huang^#¹, Guo Zhao^#¹, Peiwen Ma¹, Liang Zhang², Shuhang Wang¹, Ning Li¹

Affiliations

¹ Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Zhejiang University, Hangzhou, Zhejiang, China.

^# Contributed equally.

No abstract available

Keywords: China; drug marketing application; drug policies; policy; rare disesases.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The analysis and interpretation of the manuscript was supported by Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (Construction and Application of Clinical Trial and Institution Evaluation System 2021-I2M-1-045); Beijing Municipal Health Commission, Beijing Demonstration Research Ward BCRW20200303.